Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study CL LYMPH MYELOM LEUK
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Mol Cancer Ther
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022 EClinicalMedicine
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study Haematologica
Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids ADV SCI
Improving the EASIX' predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation BONE MARROW TRANSPL
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study LEUKEMIA LYMPHOMA
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study BRIT J HAEMATOL
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation BONE MARROW TRANSPL